Medicamentos de actualidad = Drugs of today

• 

  Año 2021, Vol. 57, Número 9

  • MONOGRAPHS

    • An update on adalimumab for pyoderma gangrenosum.

      Toshiyuki Yamamoto

      • Resumen

      págs. 535-542

      

    • Filgotinib as rheumatoid arthritis therapy.

      Andrea Becciolini, Eleonora Di Donato, Daniele Santilli, Gianluca Lucchini, Flavio Mozzani, Michele Riva, Alarico Ariani

      • Resumen

      págs. 543-550

      

    • Clinical development and current role of margetuximab for the treatment of breast cancer

      Paolo Tarantino, Jacopo Uliano, Stefania Morganti, Federica Giugliano, Edoardo Crimini, Giuseppe Curigliano

      • Resumen

      págs. 551-558

      

    • Pralsetinib for the treatment of non-small cell lung cancer.

      X.-Y. Fu, Xing-Duo Dong, L. Zeng, Charles R. Ashby, Jr., Zhe-Sheng Chen, Chao Cheng

      • Resumen

      págs. 559-569

      

    • Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.

      Qisi Lu, H. Huang, S. Tang, Ying Wang, Dong-Hua Yang

      • Resumen

      págs. 571-580

      

  • NEW PRODUCT INTROS

    • New product intros [bupivacaine/meloxicam (new combination), lazertinib, odevixibat, ozanimod hydrochloride (new indication), pegcetacoplan (first-in-class), regdanvimab, relugolix/estradiol/norethisterone acetate (new combination), savolitinib, semaglutide (new indication), serdexmethylphenidate/dexmethylphenidate (new combination), tenofovir amibufenamide fumarate, tralokinumab, upadacitinib tartrate (new indications)].

      • Resumen

      págs. 581-586